Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK25 | O00506 | 2/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12298687 | 0.81 | STK25 (0.35) | STK25NPC1RAB9ASMN1; SMN2GFER | |
| Hydrochloric Acid SCHEMBL23120669 | 0.79 | LOXL2 (0.39) | SMN1; SMN2HPGDTP53 | |
| SCHEMBL5444047 | 0.79 | STK25 (0.35) | STK25NPC1RAB9ASMN1; SMN2GFER | |
| Hydrochloric Acid SCHEMBL5444548 | 0.78 | MAPK14 (0.32) | STK25NPC1RAB9ASMN1; SMN2GFER | |
| SCHEMBL1205806 | 0.76 | ATM (0.34) | STK25KDM5BATMTSHR | |
| SCHEMBL5451411 | 0.75 | LMNA (0.37) | STK25ATMHPGDALDH1A1 | |
| SCHEMBL1206052 | 0.75 | STK25 (0.43) | STK25NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL923978 | 0.71 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2GFERATM | |
| SCHEMBL10065610 | 0.70 | GFER (0.37) | STK25KDM5BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13196200 | 0.70 | STK25 (0.34) | STK25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | STK25 3719/4885KDM5B 505/4885NPC1 242/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | STK25 3314/4885KDM5B 779/4885NPC1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.